MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Search

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.68 4.35

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.6

Max

1.69

Põhinäitajad

By Trading Economics

Sissetulek

-2.8M

-16M

Müük

-8.7M

5.5M

Kasumimarginaal

-282.723

Töötajad

81

EBITDA

-4.2M

-15M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+139.38% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. mai 2026

Turustatistika

By TradingEconomics

Turukapital

22M

674M

Eelmine avamishind

-2.67

Eelmine sulgemishind

1.68

Uudiste sentiment

By Acuity

50%

50%

168 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. apr 2026, 20:44 UTC

Tulu

Costco Reports 11% Growth in March Sales

8. apr 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8. apr 2026, 23:51 UTC

Market Talk

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8. apr 2026, 23:36 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Lower on Likely Technical Correction -- Market Talk

8. apr 2026, 22:56 UTC

Market Talk

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8. apr 2026, 22:45 UTC

Market Talk

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8. apr 2026, 22:17 UTC

Market Talk

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8. apr 2026, 21:52 UTC

Uudisväärsed sündmused

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8. apr 2026, 21:24 UTC

Tulu

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Responds to TRC Cap Mini-Tender Offer

8. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8. apr 2026, 19:44 UTC

Tulu

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8. apr 2026, 19:16 UTC

Market Talk

Hogs Follow Cutout Prices Lower -- Market Talk

8. apr 2026, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

8. apr 2026, 19:02 UTC

Market Talk

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8. apr 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8. apr 2026, 18:51 UTC

Market Talk

Global Equities Roundup: Market Talk

8. apr 2026, 18:51 UTC

Market Talk

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8. apr 2026, 18:14 UTC

Uudisväärsed sündmused

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8. apr 2026, 18:05 UTC

Uudisväärsed sündmused

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

139.38% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD  139.38%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

3

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

168 / 349 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
help-icon Live chat